• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Edwards Lifesciences Corporation

    3/26/25 4:14:10 PM ET
    $EW
    Industrial Specialties
    Health Care
    Get the next $EW alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001446989
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Edwards Lifesciences Corp
    SEC File Number
    001-15525
    Address of Issuer
    ONE EDWARDS WAY
    IRVINE
    CALIFORNIA
    92614
    Phone
    9492502500
    Name of Person for Whose Account the Securities are To Be Sold
    Ullem Scott B.
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Charles Schwab & Co., Inc.
    3000 Schwab Way
    Westlake � TX � 76262
    225001594534.0058790000003/26/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/26/2025Employee Stock Option Exercise - See RemarksEDWARDS LIFESCIENCES CORPORATIONCheckbox not checked2250003/26/2025Broker Payment for Cashless Exercise

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Scott B. Ullem
    ONE EDWARDS WAY
    IRVINE � CA � 92614
    Edwards Lifesciences Corp02/13/202511250852271.00
    Scott B. Ullem
    ONE EDWARDS WAY
    IRVINE � CA � 92614
    Edwards Lifesciences Corp02/28/202511250796327.00

    144: Remarks and Signature

    Remarks
    The options covered by this filing may be sold over various dates.
    Date of Notice
    03/26/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    08/19/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    SCOTT B ULLEM

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $EW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EW

    DatePrice TargetRatingAnalyst
    1/9/2026$97.00Hold → Buy
    TD Cowen
    12/18/2025$100.00Neutral → Overweight
    Analyst
    11/3/2025$96.00Mkt Perform → Outperform
    Raymond James
    10/29/2025Underperform → Peer Perform
    Wolfe Research
    10/29/2025$98.00Hold → Buy
    Jefferies
    10/8/2025Outperform → Perform
    Oppenheimer
    10/7/2025$88.00In-line → Outperform
    Evercore ISI
    7/29/2025$100.00Neutral → Buy
    BTIG Research
    More analyst ratings

    $EW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Edwards Lifesciences upgraded by TD Cowen with a new price target

    TD Cowen upgraded Edwards Lifesciences from Hold to Buy and set a new price target of $97.00

    1/9/26 8:27:58 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences upgraded by Analyst with a new price target

    Analyst upgraded Edwards Lifesciences from Neutral to Overweight and set a new price target of $100.00

    12/18/25 8:41:18 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences upgraded by Raymond James with a new price target

    Raymond James upgraded Edwards Lifesciences from Mkt Perform to Outperform and set a new price target of $96.00

    11/3/25 9:08:28 AM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Edwards Lifesciences to Present at the Barclays and Leerink Partners Global Healthcare Conferences

    Edwards Lifesciences Corporation (NYSE:EW) today announced its chief financial officer, Scott Ullem, is scheduled to present at two upcoming conferences: Tuesday, March 10, 2026 at 10:00 a.m. ET at the Barclays 28th Annual Global Healthcare Conference Wednesday, March 11, 2026 at 10:00 a.m. ET at the Leerink Global Healthcare Conference A live webcast of each presentation will be available on the Edwards investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakth

    2/19/26 7:05:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences to Present at Citi's 2026 Unplugged Medtech and Life Sciences Access Day

    Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate in Citi's Unplugged Medtech and Life Sciences Access Day on February 26, 2026. Scott Ullem, chief financial officer, is scheduled to present at 10:15 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeho

    2/13/26 7:05:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Reports Fourth Quarter Results

    Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook Q4 sales grew 13.3% to $1.57 billion1, constant currency2 sales grew 11.6% Q4 TAVR sales grew 12.0% to $1.16 billion1; constant currency2 sales grew 10.6% Q4 TMTT sales grew more than 40% to $156 million1 from repair and replacement therapies Q4 EPS of $0.111; adjusted2 EPS of $0.58 FY 2025 sales grew 11.5%, 10.7% constant currency2 Increased confidence in FY 2026 constant currency2 sales growth of 8 – 10% FY 2026 revenue outlook includes TMTT growing 35 – 45% to $740 – $780 million Increased confidence in FY 2026 adjusted2 EPS $

    2/10/26 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CVP, TAVR Lippis Daniel J. was granted 12,820 shares and covered exercise/tax liability with 456 shares, increasing direct ownership by 56% to 34,366 units (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    2/17/26 5:16:02 PM ET
    $EW
    Industrial Specialties
    Health Care

    CVP, Chief Financial Officer Ullem Scott B. covered exercise/tax liability with 199 shares, decreasing direct ownership by 0.50% to 39,699 units (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    2/17/26 5:16:03 PM ET
    $EW
    Industrial Specialties
    Health Care

    CEO Zovighian Bernard J sold $1,719,741 worth of shares (22,430 units at $76.67), gifted 2,920 shares, received a gift of 2,920 shares and exercised 25,350 shares at a strike of $59.26 (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    2/13/26 5:37:29 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Zovighian Bernard J covered exercise/tax liability with 4,245 shares, converted options into 6,265 shares and bought $49,753 worth of shares (580 units at $85.74), increasing direct ownership by 5% to 46,836 units (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    5/7/24 5:53:27 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    SEC Filings

    View All

    Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Edwards Lifesciences Corp (0001099800) (Filer)

    2/10/26 4:22:48 PM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Corporation filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Edwards Lifesciences Corp (0001099800) (Filer)

    1/9/26 6:51:56 PM ET
    $EW
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Edwards Lifesciences Corporation

    10-Q - Edwards Lifesciences Corp (0001099800) (Filer)

    11/5/25 4:12:51 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Leadership Updates

    Live Leadership Updates

    View All

    Edwards Lifesciences Announces CFO Transition Plan

    Edwards Lifesciences (NYSE:EW) today announced that Scott Ullem, the company's chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment of a new CFO, Ullem will continue in an advisory role. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are insp

    10/30/25 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer

    SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment of Francis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and Cardiothoracic Surgeon, brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership. As former Chief Medical Officer at Edwards Lifesciences (NYSE:EW), he played a decisive role in the development, clinical validation, and worldwide adoption of Transcatheter Aortic Valve Replacement (TAVR)—a transformative therapy now recognized as one of the most suc

    8/25/25 4:33:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor

    Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care. With more than two decades of medtech investing and operational leadership experience, Burke will help support the growth of the firm's investment platform. With over $250 million in assets under management, Intuitive Ventures invests in founders tackling large, meaningful problems that positive

    3/6/25 8:00:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Financials

    Live finance-specific insights

    View All

    Edwards Lifesciences Reports Fourth Quarter Results

    Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook Q4 sales grew 13.3% to $1.57 billion1, constant currency2 sales grew 11.6% Q4 TAVR sales grew 12.0% to $1.16 billion1; constant currency2 sales grew 10.6% Q4 TMTT sales grew more than 40% to $156 million1 from repair and replacement therapies Q4 EPS of $0.111; adjusted2 EPS of $0.58 FY 2025 sales grew 11.5%, 10.7% constant currency2 Increased confidence in FY 2026 constant currency2 sales growth of 8 – 10% FY 2026 revenue outlook includes TMTT growing 35 – 45% to $740 – $780 million Increased confidence in FY 2026 adjusted2 EPS $

    2/10/26 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences to Host Earnings Conference Call on February 10, 2026

    Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended December 31, 2025 after the market closes on Tuesday, February 10, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians an

    2/3/26 7:05:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference

    Innovation with Purpose, Powered by Science, Centered on Patients: Edwards' Commitment to Drive Value for the Healthcare Ecosystem Edwards Lifesciences (NYSE:EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated growth, Edwards is uniquely positioned with leading therapies across its core structural heart innovations for patients with aortic stenosis (AS), mitral regurgitation (MR), tricuspid regurgitation (TR) and pulmonic diseases, and expanding into emerging opportunities to advance treatments for aortic regurgitation (AR) and structural heart failure. "As we enter 202

    12/4/25 9:00:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Edwards Lifesciences Corporation

    SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)

    11/8/24 10:34:33 AM ET
    $EW
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Edwards Lifesciences Corporation

    SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

    10/4/24 2:14:28 PM ET
    $EW
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Edwards Lifesciences Corporation (Amendment)

    SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

    2/13/24 5:04:42 PM ET
    $EW
    Industrial Specialties
    Health Care